Ardelyx Faces Class Action Over IBSRELA Revenue Shortfall and Guidance Cut
A class-action lawsuit alleges Ardelyx misrepresented IBSRELA and XPHOZAH performance during 2025-2026, following a Q2 2026 revenue miss and guidance reductions. The stock fell ~18% after the Aug 7 release as payer barriers and tighter prior-authorization were cited as constraints on new-patient starts. The legal overhang adds near-term volatility and could influence sales execution and cash-flow visibility.
View signal analysis